Silverfin false false 31/12/2024 01/01/2024 31/12/2024 Dr Y Matsumiya 01/03/2024 11/03/2021 K Tokuoka 11/03/2021 Mr R Tsai 11/03/2021 01 July 2025 The principal activity of the company was that of research and experimental development on biotechnology. 13260481 2024-12-31 13260481 bus:Director1 2024-12-31 13260481 bus:Director2 2024-12-31 13260481 bus:Director3 2024-12-31 13260481 2023-12-31 13260481 core:CurrentFinancialInstruments 2024-12-31 13260481 core:CurrentFinancialInstruments 2023-12-31 13260481 core:ShareCapital 2024-12-31 13260481 core:ShareCapital 2023-12-31 13260481 core:RetainedEarningsAccumulatedLosses 2024-12-31 13260481 core:RetainedEarningsAccumulatedLosses 2023-12-31 13260481 core:OtherPropertyPlantEquipment 2023-12-31 13260481 core:OtherPropertyPlantEquipment 2024-12-31 13260481 bus:OrdinaryShareClass1 2024-12-31 13260481 2024-01-01 2024-12-31 13260481 bus:FilletedAccounts 2024-01-01 2024-12-31 13260481 bus:SmallEntities 2024-01-01 2024-12-31 13260481 bus:AuditExemptWithAccountantsReport 2024-01-01 2024-12-31 13260481 bus:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 13260481 bus:Director1 2024-01-01 2024-12-31 13260481 bus:Director2 2024-01-01 2024-12-31 13260481 bus:Director3 2024-01-01 2024-12-31 13260481 core:OtherPropertyPlantEquipment core:TopRangeValue 2024-01-01 2024-12-31 13260481 2023-01-01 2023-12-31 13260481 core:OtherPropertyPlantEquipment 2024-01-01 2024-12-31 13260481 bus:OrdinaryShareClass1 2024-01-01 2024-12-31 13260481 bus:OrdinaryShareClass1 2023-01-01 2023-12-31 iso4217:GBP xbrli:pure xbrli:shares

Company No: 13260481 (England and Wales)

LUCA SCIENCE U.K. LIMITED

UNAUDITED FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2024
PAGES FOR FILING WITH THE REGISTRAR

LUCA SCIENCE U.K. LIMITED

UNAUDITED FINANCIAL STATEMENTS

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2024

Contents

LUCA SCIENCE U.K. LIMITED

BALANCE SHEET

AS AT 31 DECEMBER 2024
LUCA SCIENCE U.K. LIMITED

BALANCE SHEET (continued)

AS AT 31 DECEMBER 2024
Note 2024 2023
£ £
Fixed assets
Tangible assets 3 368 665
368 665
Current assets
Debtors 4 24,428 938
Cash at bank and in hand 54,524 115,565
78,952 116,503
Creditors: amounts falling due within one year 5 ( 430,913) ( 452,073)
Net current liabilities (351,961) (335,570)
Total assets less current liabilities (351,593) (334,905)
Net liabilities ( 351,593) ( 334,905)
Capital and reserves
Called-up share capital 6 1,000 1,000
Profit and loss account ( 352,593 ) ( 335,905 )
Total shareholder's deficit ( 351,593) ( 334,905)

For the financial year ending 31 December 2024 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

These financial statements have been prepared in accordance with the provisions of FRS 102 Section 1A – small entities. The financial statements of Luca Science U.K. Limited (registered number: 13260481) were approved and authorised for issue by the Board of Directors on 01 July 2025. They were signed on its behalf by:

Mr R Tsai
Director
LUCA SCIENCE U.K. LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2024
LUCA SCIENCE U.K. LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2024
1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.

General information and basis of accounting

Luca Science U.K. Limited (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is 264 Banbury Road, Oxford, OX2 7DY, United Kingdom.

The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

Going concern

The directors have received confirmation that the group will continue to support ongoing operations, and have assessed the Balance Sheet and likely future cash flows at the date of approving these financial statements. The directors have a reasonable expectation that the Company has adequate resources to continue in operational existence and to meet its financial obligations as they fall due for at least 12 months from the date of signing these financial statements. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

Group accounts exemption

Group accounts exemption s400
The Company has taken advantage of the exemption under section 400 of the Companies Act 2006 not to prepare consolidated accounts. The financial statements present information about the company as an individual entity and not about its group.

Luca Science U.K. Limited is a wholly owned subsidiary of Luca Science Inc and the results of Luca Science U.K. Limited are included in the consolidated financial statements of Luca Science Inc which are available from 3-8-3, Nihonbashi Honcho, Chuo-ku, Tokyo, 103-0023, Japan.

Foreign currency

Transactions in foreign currencies are recorded at the rate of exchange at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the Balance Sheet date are reported at the rates of exchange prevailing at that date.

Exchange differences are recognised in the Profit and Loss Account in the period in which they arise except for exchange differences arising on gains or losses on non-monetary items which are recognised in the Statement of Comprehensive Income.

Employee benefits

Short term benefits
The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

Termination benefits are recognised as an expense when the Company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

Defined contribution schemes
The Company operates a defined contribution scheme. The amount charged to the Profit and Loss Account in respect of pension costs and other post-retirement benefits is the contributions payable in the financial year. Differences between contributions payable in the financial year and contributions actually paid are included as either accruals or prepayments in the Balance Sheet.

Taxation

Current tax
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Tangible fixed assets

Tangible fixed assets are stated at cost or valuation, net of depreciation and any provision for impairment. Depreciation is provided on all tangible fixed assets, other than investment property and freehold land, at rates calculated to write off the cost or valuation, less estimated residual value, of each asset on a straight-line or reducing balance basis over its expected useful life, as follows:

Plant and machinery etc. 4 years straight line

Depreciation methods, useful lives and residual values are reviewed at each balance sheet date. The selection of these residual values and estimated lives requires the exercise of judgement. The directors are required to assess whether there is an indication of impairment to the carrying value of assets. In making that assessment, judgements are made in estimating value in use. The directors consider that the individual carrying values of assets are supportable by their value in use.

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

Impairment of assets

Assets, other than those measured at fair value, are assessed for indicators of impairment at each Balance Sheet date. If there is objective evidence of impairment, an impairment loss is recognised in the Profit and Loss Account as described below.

Non-financial assets
At each balance sheet date, the company reviews its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss.

If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). The recoverable amount of an asset is the higher of its fair value less costs to sell and its value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in creditors: amounts falling due within one year.

Financial instruments

Financial assets and financial liabilities are recognised when the Company becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities.

Financial assets and liabilities are only offset in the Balance Sheet when, and only when there exists a legally enforceable right to set off the recognised amounts and the Company intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Basic financial assets
Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities
Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

2. Employees

2024 2023
Number Number
Monthly average number of persons employed by the Company during the year, including directors 2 2

3. Tangible assets

Plant and machinery etc. Total
£ £
Cost
At 01 January 2024 1,190 1,190
At 31 December 2024 1,190 1,190
Accumulated depreciation
At 01 January 2024 525 525
Charge for the financial year 297 297
At 31 December 2024 822 822
Net book value
At 31 December 2024 368 368
At 31 December 2023 665 665

4. Debtors

2024 2023
£ £
Corporation tax 23,921 0
Other debtors 507 938
24,428 938

5. Creditors: amounts falling due within one year

2024 2023
£ £
Trade creditors 894 1,166
Other taxation and social security 0 1,075
Other creditors 430,019 449,832
430,913 452,073

6. Called-up share capital

2024 2023
£ £
Allotted, called-up and fully-paid
100 Ordinary shares of £ 10.00 each 1,000 1,000

7. Related party transactions

The company has taken advantage of the exemption allowed by FRS 102 Section 33.1A and has not disclosed related party transactions with fellow wholly owned subsidiaries of LUCA Science Inc.